Quantcast

Latest Edwards Lifesciences Corporation Stories

2014-09-13 12:20:33

Transcatheter Valve Durability Sustained Through Five Years WASHINGTON, Sept. 13, 2014 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced the presentation of five-year clinical outcomes for inoperable patients treated in The PARTNER Trial, the world's only prospective randomized trial for transcatheter aortic valve replacement (TAVR) in patients deemed too sick for open-heart...

2014-09-03 08:34:47

IRVINE, Calif. and IRVING, Texas, Sept. 3, 2014 /PRNewswire/ -- Novation and Edwards Lifesciences Corporation (NYSE: EW) today announced they have entered into a three-year, sole-source strategic relationship that provides the world's market leading heart valve therapies to the more than 100,000 members and affiliates of VHA, UHC, Children's Hospital Association and Provista. The new agreement with Edwards for its heart valve product portfolio enables Novation to enter the heart...

2014-07-29 16:26:42

- Global THV Sales Grew 21% IRVINE, Calif., July 29, 2014 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today reported net income for the quarter ended June 30, 2014 of $547.0 million, or $5.09 per diluted share, and non-GAAP net income of $94.0 million, or $0.88 per diluted share. Net income for the same period a year earlier was $93.3 million, or $0.81 per diluted share, and non-GAAP net income was...

2014-07-22 16:27:40

WASHINGTON, July 22, 2014 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced that Edwards' Chairman and CEO Michael A. Mussallem today served as an expert panelist at the invitation of the United States Energy and Commerce Committee's Subcommittee on Health to discuss medical device innovation at its hearing, "21(st) Century Cures: Examining Barriers to Ongoing Evidence Development and...

2014-07-15 12:28:36

IRVINE, Calif., July 15, 2014 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, plans to announce its operating results for the quarter ended June 30, 2014 after the market closes on Tuesday, July 29, 2014 and will host a conference call at 5:00 p.m. ET that day to discuss its results. http://photos.prnewswire.com/prnvar/20140714/126903 To participate in the conference call, dial (877) 407-8037...

2014-06-30 08:31:38

ClearSight system enables clinicians to reduce risk of post-surgical complications IRVINE, Calif., June 30, 2014 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received U.S. Food and Drug Administration (FDA) clearance for the ClearSight system. To view the multimedia assets associated with this release, please click:...

2014-06-16 20:21:59

FDA Approval Includes High-Risk and Inoperable Indications, Transfemoral and Alternative Access Systems IRVINE, Calif., June 16, 2014 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that it has received United States Food and Drug Administration (FDA) approval for its Edwards SAPIEN XT transcatheter aortic heart valve for the treatment of high-risk and inoperable patients...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related